Antibody-mediated rejection: Emergence of animal models to answer clinical questions: Minireview

American Journal of Transplantation

Volumn 10, Issue 5, 2010, Pages 1135-1142

  Baldwin Iii, William M ^a   Valujskikh, Anna ^a   Fairchild, Robert L ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute allograft rejection; Allograft vasculopathy; Animal models; Antibody mediated rejection; Transplant rejection

Indexed keywords

ALLOANTIBODY; ANTIBODY; CD20 ANTIGEN; CD31 ANTIGEN; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5A; DECAY ACCELERATING FACTOR; FC RECEPTOR; IMMUNOGLOBULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; RAPAMYCIN; RITUXIMAB; VASCULAR CELL ADHESION MOLECULE 1;

ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIINFLAMMATORY ACTIVITY; ARTERY ENDOTHELIUM; CAPILLARY ENDOTHELIUM; CARDIAC GRAFT REJECTION; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; EXPERIMENTAL MODEL; HUMAN; IN VITRO STUDY; KIDNEY GRAFT REJECTION; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; SHORT SURVEY; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES; ENDOTHELIAL CELLS; GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS; KIDNEY; MODELS, ANIMAL;

EID: 77951236604     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03065.x     Document Type: Short Survey

References (71)

1. Williams GM. Clinical aspects of allograft rejection. Transplant Proc 1974 6 (4 Suppl 1 71 77.
2. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969 280 : 735 739.
3. Carpenter CB, d'Apice AJ, Abbas AK. The role of antibodies in the rejection and enhancement of organ allografts.?7318. Adv Immunol 1976 22 : 1 65.
4. Tilney NL, Kupiec-Weglinski JW, Heidecke CD, Lear PA, Strom TB. Mechanisms of rejection and prolongation of vascularized organ allografts. Immunol Rev 1984 77 : 185 216.
5. Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation 1990 49 : 85 91. (Pubitemid 20051591)
6. Halloran PF, Schlaut J, Solez K, Srinivasa NS. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992 53 : 550 555.
7. Feucht HE, Felber E, Gokel MJ et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991 86 : 464 470.
8. Collins AB, Schneeberger EE, Pascual MA et al. Complement activation in acute humoral renal allograft rejection: Diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999 10 : 2208 2214.
9. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria - an addition to the banff 97 classification of renal allograft rejection. Am J Transplant 2003 3 : 708 714. (Pubitemid 36745243)
10. Takemoto SK, Zeevi A, Feng S et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004 4 : 1033 1041. (Pubitemid 38868592)
11. Mengel M, Bogers J, Bosmans JL et al. Incidence of C4d stain in protocol biopsies from renal allografts: Results from a multicenter trial. Am J Transplant 2005 5 : 1050 1056. (Pubitemid 40571253)
12. Mauiyyedi S, Colvin RB. Humoral rejection in kidney transplantation: New concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens 2002 11 : 609 618. (Pubitemid 35440842)
13. Loupy A, Suberbielle-Boissel C, Hill GS et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009 9 : 2561 2570.
14. Kraus ES, Parekh RS, Oberai P et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: Incidence and correlations. Am J Transplant 2009 9 : 1826 1834.
15. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d Staining. Am J Transplant 2009 9 : 2312 2323.
16. Reed EF, Demetris AJ, Hammond E et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006 25 : 153 159. (Pubitemid 43156365)
17. Minami K, Murata K, Lee C-Y et al. C4d deposition and clearance in cardiac transplants correlates with alloantibody levels and rejection in rats. Am J Transplant 2006 6 : 923 932. (Pubitemid 44356642)
18. Qian Z, Lee CY, Murata K et al. Antibody and complement mediated injury in transplants following sensitization by allogeneic blood transfusion. Transplantation 2006 82 : 857 864. (Pubitemid 44564029)
19. Murata K, Fox-Talbot K, Qian Z et al. Synergistic deposition of C4d by complement and non-complement activating antibodies in cardiac transplants. Am J Transpl 2007 7 : 2605 2614. (Pubitemid 47561614)
20. Nozaki T, Amano H, Bickerstaff A et al. Antibody-mediated rejection of cardiac allografts in CCR5-deficient recipients. J Immunol 2007 179 : 5238 5245.
21. Bickerstaff A, Nozaki T, Wang JJ et al. Acute humoral rejection of renal allografts in CCR5(-/-) recipients. Am J Transplant 2008 8 : 557 566. (Pubitemid 351287552)
22. Wasowska BA, Qian Z, Cangello DL et al. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice. Transplantation 2001 71 : 727 736. (Pubitemid 32377270)
23. Wang H, Jiang J, Liu W et al. Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine. Transplantation 2005 79 : 1121 1127. (Pubitemid 40664008)
24. Rother RP, Arp J, Jiang J et al. C5 blockade with conventional immunosuppression induces long-term graft survival in presensitized recipients. Am J Transplant 2008 8 : 1129 1142.
25. Gueler F, Rong S, Gwinner W et al. Complement 5a receptor inhibition improves renal allograft survival. J Am Soc Nephrol 2008 19 : 2302 2312.
26. Jindra PT, Hsueh A, Hong L et al. Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol 2008 180 : 2214 2224.
27. Uehara S, Chase C, Cornell L, Madsen J, Russell P, Colvin R. Chronic cardiac transplant arteriopathy in mice: Relationship of alloantibody, C4d deposition and neointimal fibrosis. Am J Transpl 2007 7 : 57 65. (Pubitemid 44952856)
28. Lederer SR, Kluth-Pepper B, Schneeberger H, Albert E, Land W, Feucht HE. Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int 2001 59 : 334 341. (Pubitemid 32055242)
29. Daar AS, Fuggle SV, Fabre JW, Ting A, Morris PJ. The detailed distribution of MHC Class II antigens in normal human organs. Transplantation 1984 38 : 293 298. (Pubitemid 14035182)
30. Choo JK, Seebach JD, Nickeleit V et al. Species differences in the expression of major histocompatibility complex class II antigens on coronary artery endothelium: Implications for cell-mediated xenoreactivity. Transplantation 1997 64 : 1315 1322. (Pubitemid 27495966)
31. Goes N, Urmson J, Vincent D, Halloran PF. Acute renal injury in the interferon-gamma gene knockout mouse: Effect on cytokine gene expression. Transplantation 1995 60 : 1560 1564. (Pubitemid 26012693)
32. Goes N, Sims T, Urmson J, Vincent D, Ramassar V, Halloran PF. Disturbed MHC regulation in the IFN-gamma knockout mouse. Evidence for three states of MHC expression with distinct roles for IFN-gamma. J Immunol 1995 155 : 4559 4566.
33. Meehan SM, Limsrichamrern S, Manaligod JR et al. Platelets and capillary injury in acute humoral rejection of renal allografts. Hum Pathol 2003 34 : 533 540. (Pubitemid 36750364)
34. Morrell CN, Murata K, Swaim AM et al. In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody. Circ Res 2008 102 : 777 785. (Pubitemid 351521583)
35. Morrell CN, Sun H, Swaim AM, Baldwin WM, III. Platelets, an inflammatory force in transplantation. Am J Transplant 2007 7 : 2447 2454.
36. Kirk AD, Morrell CN, Baldwin WM, 3rd. Platelets influence vascularized organ transplants from start to finish. Am J Transplant 2009 9 : 14 22.
37. Lucchiari N, Panajotopoulos N, Xu C et al. Antibodies eluted from acutely rejected renal allografts bind to and activate human endothelial cells. Hum Immunol 2000 61 : 518 527. (Pubitemid 30238283)
38. Yamakuchi M, Kirkiles-Smith NC, Ferlito M et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci U S A 2007 104 : 1301 1306. (Pubitemid 46183999)
39. Mahesh B, Leong HS, McCormack A, Sarathchandra P, Holder A, Rose ML. Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. Am J Pathol 2007 170 : 1415 1427. (Pubitemid 47339348)
40. Zhang X, Reed EF. Effect of antibodies on endothelium. Am J Transplant 2009 9 : 2459 2465.
41. Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 1994 179 : 985 992. (Pubitemid 24065656)
42. Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989 264 : 9053 9060. (Pubitemid 19151636)
43. Lee C-Y, Reynolds M, Garyu J, Baldwin WM, III., Wasowska BA. The involvement of FcR mechanisms in antibody-mediated rejection. Transplantation 2007 84 : 1324 1334. (Pubitemid 351339321)
44. Nimmerjahn F, Anthony RM, Ravetch JV. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci U S A 2007 104 : 8433 8437. (Pubitemid 47175505)
45. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1995 1 : 237 243.
46. Rook GA, Steele J, Brealey R et al. Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. J Autoimmun 1991 4 : 779 794.
47. Van Beneden K, Coppieters K, Laroy W et al. Reversible changes in serum immunoglobulin galactosylation during the immune response and treatment of inflammatory autoimmune arthritis. Ann Rheum Dis 2009 68 : 1360 1365.
48. Mauiyyedi S, Pelle PD, Saidman S et al. Chronic humoral rejection: Identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001 12 : 574 582. (Pubitemid 32180027)
49. Regele H, Bohmig GA, Habicht A et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: A contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002 13 : 2371 2380. (Pubitemid 34925248)
50. Wu GW, Kobashigawa JA, Fishbein MC et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant 2009 28 : 417 422.
51. Smith RN, Kawai T, Boskovic S et al. Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys. Am J Transplant 2008 8 : 1662 1672.
52. Atkinson C, Southwood M, Pitman R, Phillpotts C, Wallwork J, Goddard M. Angiogenesis occurs within the intimal proliferation that characterizes transplant coronary artery vasculopathy. J Heart Lung Transplant 2005 24 : 551 558. (Pubitemid 40693877)
53. Booth RF, Martin JF, Honey AC, Hassall DG, Beesley JE, Moncada S. Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation. Atherosclerosis 1989 76 : 257 268. (Pubitemid 19101045)
54. Jeannet M, Pinn VW, Flax MH, Winn HJ, Russell PS. Humoral antibodies in renal allotransplantation in man. N Engl J Med 1970 282 : 111 117.
55. Busch GJ, Reynolds ES, Galvanek EG, Braun WE, Dammin GJ. Human renal allografts. The role of vascular injury in early graft failure. Medicine 1971 50 : 29 83.
56. Galvani S, Auge N, Calise D et al. HLA class I antibodies provoke graft arteriosclerosis in human arteries transplanted into SCID/beige mice. Am J Transplant 2009 9 : 2607 2614.
57. Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts II. Importance of humoral immunity. J Immunol 1994 152 : 5135 5141.
58. Chatterjee TK, Stoll LL, Denning GM et al. Proinflammatory phenotype of perivascular adipocytes: Influence of high-fat feeding. Circ Res 2009 104 : 541 549.
59. Tuzcu EM, Kapadia SR, Sachar R et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol 2005 45 : 1538 1542. (Pubitemid 40615631)
60. Kaliss N, Sinclair NR, Cantrell JL. Immunological enhancement of a murine tumor allograft by passive alloantibody IgG and F(ab')2. Eur J Immunol 1976 6 : 38 42.
61. Batchelor JR. The riddle of kidney graft enhancement. Transplantation 1978 26 : 139 141.
62. Opelz G, Terasaki PI. Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med 1978 299 : 799 803. (Pubitemid 9044523)
63. Platt JL. C4d and the fate of organ allografts. J Am Soc Nephrol 2002 13 : 2417 2419.
64. Haas M, Rahman MH, Racusen LC et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: Correlation with histologic findings. Am J Transplant 2006 6 : 1829 1840. (Pubitemid 44024954)
65. Tan CD, Sokos GG, Pidwell DJ et al. Correlation of donor-specific antibodies, complement and its regulators with graft dysfunction in cardiac antibody-mediated rejection. Am J Transplant 2009 9 : 2075 2084.
66. Brodsky SV, Nadasdy GM, Pelletier R et al. Expression of the decay-accelerating factor (CD55) in renal transplants-a possible prediction marker of allograft survival. Transplantation 2009 88 : 457 464.
67. Navratil JS, Watkins SC, Wisnieski JJ, Ahearn JM. The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells. J Immunol 2001 166 : 3231 3239.
68. Csencsits K, Burrell BE, Lu G, Eichwald EJ, Stahl GL, Bishop DK. The classical complement pathway in transplantation: Unanticipated protective effects of C1q and role in inductive antibody therapy. Am J Transplant 2008 8 : 1622 1630.
69. Locke JE, Magro CM, Singer AL et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009 9 : 231 235.
70. Beers SA, Chan CH, James S et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 2008 112 : 4170 4177.
71. Tedder TF. CD19: A promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 2009 5 : 572 577.